Surgery plus chemotherapy for stomach cancer in the belly lining
Part of Cancer, Digestive system clinical trials.
This study tests whether a thorough surgery to remove stomach cancer in the abdomen, followed by chemotherapy given through the belly and by vein, can improve outcomes. It’s for people newly diagnosed with stomach cancer that has limited spread to the belly lining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 to 75 years old.
- Blood test results are strong enough (white blood cells, neutrophils, and platelets) and kidney and liver tests are within limits.
- You can do most normal activities (ECOG 0 or 1).
- Your stomach cancer is newly diagnosed, and spread is limited to the belly lining (PCI 10 or less) or your belly fluid test is positive (CY1/P0).
- You have not had chemotherapy for this cancer before surgery (no pre-op chemo by vein or into the abdomen).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if surgery to remove the stomach and some tumors, after a few months of chemo, helps people whose stomach cancer has spread to only a few nearby spots (like the lining of the belly, liver, or lymph nodes) live longer compared to chemo alone.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This Phase 2 trial studies a combination treatment for stomach (or stomach-to-esophagus) cancer that has spread to the belly lining. It tests whether adding the immunotherapy drug sintilimab to a procedure called HIPEC can improve outcomes for people who have not had prior treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial studies chemotherapy given before surgery for advanced stomach (gastric) cancer, including treatment when cancer may be on the stomach lining (peritoneum). It may help shrink tumors and improve outcomes for people who meet specific marker and staging requirements.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.